Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that address significant unmet medical needs. The company's mission is to enhance the treatment of renal and gastrointestinal diseases through its proprietary drug discovery and design platform.
One of Ardelyx's lead products is tenapanor, which has been developed to reduce the absorption of dietary sodium and phosphorus. It is being investigated for multiple conditions, including hyperphosphatemia in patients with end-stage renal disease on dialysis and irritable bowel syndrome with constipation (IBS-C). The company has made significant strides in these areas, recently gaining FDA approval for tenapanor under the brand names IBSRELA® and XPHOZAH®. IBSRELA is targeted at treating IBS-C, while XPHOZAH is aimed at controlling serum phosphorus levels in patients with chronic kidney disease on dialysis.
Ardelyx has also forged strategic partnerships to extend the reach of its therapies globally. This includes collaborations with Kyowa Kirin in Japan, Fosun Pharma in China, and Knight Therapeutics in Canada. Notably, Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan, while a New Drug Application for the same indication is under review in China.
In its latest financial update, Ardelyx reported strong revenue growth for IBSRELA, achieving approximately $80 million in net product sales revenue for its first full year of commercialization. The company anticipates even higher sales in 2024, projecting revenues between $140 million and $150 million. Additionally, XPHOZAH, which launched in November 2023, recorded $2.5 million in net product sales revenue in its first quarter. To support these products, Ardelyx is investing in expanding its sales team and digital capabilities, as well as enhancing its patient services through the ArdelyxAssist™ program.
As of December 31, 2023, Ardelyx maintained a strong cash position with approximately $184 million in cash, cash equivalents, and short-term investments. The company’s financial stability and continuous investment in its robust R&D pipeline underscore its commitment to advancing the standard of care for patients with renal and gastrointestinal diseases.
Ardelyx continues to engage with the medical community and investors through various platforms, including regular webcasts and conferences. The company remains focused on executing its commercial strategy, expanding market penetration, and exploring new avenues for growth through internal development and external partnerships.
Ardelyx, Inc. (Nasdaq: ARDX) announced the publication of its long-term 52-week Phase 3 PHREEDOM trial results in the journal Kidney360. The trial evaluated tenapanor monotherapy for controlling serum phosphorus in chronic kidney disease patients on dialysis. Results showed a significant reduction in phosphorus levels, with decrease from 7.7 mg/dL to 5.1 mg/dL. The trial supports tenapanor's safety and efficacy, presenting it as a promising treatment option for managing hyperphosphatemia. The study's findings highlight the potential of tenapanor to improve patient outcomes in a challenging treatment area.
Ardelyx, Inc. (Nasdaq: ARDX) reported its second quarter 2021 financial results, revealing a net loss of $45.2 million, up from $25.0 million a year prior. Revenue for the quarter was $1.3 million, primarily from a collaboration with Kyowa Kirin. The company faces challenges as the FDA issued a Complete Response Letter for its tenapanor NDA, prompting a restructuring plan expected to incur $3.4 million in charges but reduce annual cash compensation costs by $17 million. As of June 30, 2021, Ardelyx held $171.8 million in cash and equivalents.
Ardelyx, Inc. (Nasdaq: ARDX) announced it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for tenapanor aimed at controlling serum phosphorus in CKD patients on dialysis. The FDA acknowledged substantial evidence of tenapanor's effectiveness but deemed the treatment effect as small and unclear in clinical significance. Ardelyx must conduct further trials for approval. The company plans to request a Type A meeting with the FDA to discuss the CRL. Ardelyx reported $171.8 million in cash at the end of Q2 2021.
Ardelyx, Inc. (Nasdaq: ARDX), announced that the FDA identified deficiencies in its New Drug Application (NDA) for tenapanor, intended for controlling serum phosphorus in chronic kidney disease patients on dialysis. The FDA's letter, received on July 13, 2021, prevents discussions on labeling and post-marketing commitments. The company has requested a meeting to understand these deficiencies but was denied. Key concerns include the treatment effect size and its clinical relevance. Ardelyx plans to address these issues as they work towards regulatory approval.
Ardelyx, Inc. (Nasdaq: ARDX) presented new data on tenapanor at the ERA-EDTA Virtual Congress 2021. Interim results from the OPTIMIZE study indicate that tenapanor significantly improves phosphorus control in patients with chronic kidney disease (CKD) on dialysis. Approximately 50% of previously uncontrolled patients achieved target phosphorus levels. Additionally, tenapanor demonstrated lower rates of deaths and hospitalizations versus sevelamer in the PHREEDOM study. Ardelyx continues to advance tenapanor while its NDA is under FDA review, with a PDUFA date of July 29, 2021.
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company, announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 p.m. ET. The live webcast can be accessed on the company's Investor website, with a replay available for 60 days. Ardelyx is focused on developing first-in-class medicines for kidney and cardiorenal diseases, including tenapanor, which is currently under FDA review for managing serum phosphorus in CKD patients. The company also received FDA approval for IBSRELA® in September 2020.
Ardelyx, Inc. (Nasdaq: ARDX) has announced its Q1 2021 financial results, highlighting a revenue of $6.6 million, primarily from a $5 million milestone from Kyowa Kirin. The company's cash position stood at $178.2 million, down from $188.6 million at year-end 2020. R&D expenses surged by 29% to $20.5 million, while G&A expenses skyrocketed by 140% to $17.1 million. Net loss for the quarter was $33.2 million, compared to $22.4 million in Q1 2020. The PDUFA date for tenapanor is extended to July 29, 2021.
Ardelyx, Inc. (Nasdaq: ARDX) announced a three-month extension of the PDUFA date for tenapanor, aimed at controlling serum phosphorus in adult CKD patients on dialysis, now set for July 29, 2021. This decision follows FDA requests for additional analyses regarding tenapanor's clinical data. CEO Mike Raab expressed disappointment but acknowledged the impact of the COVID-19 pandemic on the FDA's operations. Tenapanor's NDA is backed by extensive clinical trials involving over 1,000 patients, demonstrating its potential efficacy in managing hyperphosphatemia.
On April 12, 2021, Ardelyx (Nasdaq: ARDX) granted stock options for 125,622 shares and restricted stock units for 26,315 shares to its new Chief People Officer, Sarah O'Brien, under its Employment Commencement Incentive Plan. The option's exercise price is $7.03, equal to Ardelyx's closing stock price on that date. The awards vest over four years, contingent on continued employment. Ardelyx is advancing its product candidate, tenapanor, for FDA review, with a decision expected by April 29, 2021, indicating ongoing progress in their pipeline focused on kidney diseases.
Ardelyx, Inc. (Nasdaq: ARDX) announced that its partner Kyowa Kirin has begun four Phase 3 clinical trials in Japan for tenapanor, aimed at treating hyperphosphatemia. This milestone triggers a $5 million payment to Ardelyx. The trials include various study designs assessing tenapanor's effectiveness in patients with chronic kidney disease (CKD) on dialysis. Ardelyx is expecting a PDUFA date on April 29, 2021, for tenapanor's review by the FDA. The collaboration could yield up to $55 million in total development milestones and significant sales royalties.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
What is Ardelyx, Inc. focused on?
What are the main products of Ardelyx?
How has Ardelyx performed financially in recent years?
What strategic partnerships does Ardelyx have?
What is tenapanor used for?
What is the ArdelyxAssist™ program?
What is the financial status of Ardelyx?
Where can investors find more information about Ardelyx?
What recent achievements has Ardelyx made?
What future plans does Ardelyx have?
